Write in a clean editor, then format for Hematology/Oncology and Stem Cell Therapy in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Hematology/Oncology and Stem Cell Therapy is a peer-reviewed journal published by Elsevier, covering Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Hematology/Oncology and Stem Cell Therapy 12 (2023) 45–58.
Formats any DOI in Hematology/Oncology and Stem Cell Therapy style. No sign-up. |
| Publishes research in | Hematopoietic Stem Cell Transplantation Acute Myeloid Leukemia Research Lymphoma Diagnosis and Treatment Acute Lymphoblastic Leukemia research Hemoglobinopathies and Related Disorders |
| ISSN | 1658-3876 |
| Citation impact (2-yr) | 0.81 |
| h-index | 40 |
| i10-index | 286 |
| Total citations | 9,312 |
| Open access | Yes |
| Top institutions publishing here | King Faisal Specialist Hospital & Research Centre |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Natural killer (NK) cells constitute our bodies' frontline defense system, guarding against tumors and launching attacks against infections. The activities of NK cells are regulated by the interaction of various receptors expressed on their surfaces with cell surface ligands. While the role of NK cells in controlling tumor activity is relatively clear, the fact that…
The prevalence of autologous and allogeneic hematopoietic cell transplantation (HCT) survivors continues to increase. Among patients whose disease remains in remission for the first 2-5years after transplantation, it is estimated that approximately 80-90% will be alive over the subsequent 10years. However, the relative mortality rates of such patients continue to remain higher than those of…
Cancer is the second leading cause of death in Jordan after cardiovascular diseases. Due to increase in life expectancy and prolonged exposure to risk factors, cancer mortality and morbidity are expected to increase as the young population ages. This increase will constitute a challenging burden on healthcare systems in Jordan and many other neighboring countries.…
Numerous studies have been published regarding outcomes of cancer patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causing the coronavirus disease 2019 (COVID-19) infection. However, most of these are single-center studies with a limited number of patients. To better assess the outcomes of this new infection in this subgroup of susceptible…
BACKGROUND: Thyroid cancer is the second most common malignancy among females at King Faisal Specialist Hospital and Research Centre (KFSH&RC) and in Saudi Arabia, accounting for about 11% of all newly diagnosed female cancers in the country in 2008. Over the past several decades, an increasing incidence of thyroid cancer has been reported in the…
